Navigation Links
New oral agents may prevent injury after radiation exposure
Date:7/10/2009

(Boston) Researchers from Boston University School of Medicine (BUSM) and collaborators have discovered and analyzed several new compounds, collectively called the ''EUK-400 series,'' which could someday be used to prevent radiation-induced injuries to kidneys, lungs, skin, intestinal tract and brains of radiological terrorism victims. The findings, which appear in the June issue of the Journal of Biological Inorganic Chemistry, describe new agents which can be given orally in pill form, which would more expedient in an emergency situation.

These agents are novel synthetic "antioxidants" that protect tissues against the kind of damage caused by agents such as "free radicals." Free radicals, and similar toxic byproducts formed in the body, are implicated in many different types of tissue injury, including those caused by radiation exposure. Often, this kind of injury occurs months to years after radiation exposure. The BUSM researchers and their colleagues are developing agents that prevent injury even when given after the radiation exposure.

This paper describes a newer class of compounds, the ''EUK-400 series,'' that are designed to be given as a pill. According to the researchers, experiments described in their paper prove that these agents are orally active. They also show that the new agents have several desirable "antioxidant" activities, and protect cells in a "cell death" model.

These same BUSM researchers and collaborators had previously discovered novel synthetic antioxidants that effectively mitigate radiation injuries, but had to be given by injection. "We have developed some of these agents and have studied them for over 15 years beginning with our work at the local biotechnology company Eukarion," said senior author Susan Doctrow, PhD, a research associate professor of medicine at BUSM's Pulmonary Center. "These injectible antioxidants are very effective, but there has also been a desire to have agents that can be given orally. A pill would be more feasible than an injection to treat large numbers of people in an emergency scenario," she adds.

Future studies will focus on the EUK-400 compounds' effects in various experimental models for radiation injury. Data showing their benefits in models for radiation injury in blood vessel cells have been presented at two major scientific conferences and will be the topic of future publication. More broadly, beyond the potential for treating victims of radiological terrorism, these compounds could also be useful drugs against a variety of diseases where an effective antioxidant has potential benefits, for example, various neurological, pulmonary, cardiovascular, and autoimmune disorders. Previously, Doctrow's lab and others have published studies showing that the injectible versions of these compounds are beneficial in models for several such diseases.


'/>"/>

Contact: Allison Rubin
allison.rubin@gmail.com
617-638-8490
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. ABR-Affinity BioReagents Expands 100% Quality Guarantee
4. Inside job: new radioactive agents for colon cancer work inside cells
5. ABR -- Affinity BioReagents Announces Launch of New Website
6. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
7. Controversial physical agents directive postponed
8. Health Insurance Agents Warn Against Imposing a Health Care Reform Tax in California
9. ABR-Affinity BioReagents Announces Its Continued Support for the Society for Neuroscience Annual Meeting in San Diego, November 3 - 7, 2007
10. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies
11. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. The ... for the mass media launching of story movements to highlight what's most unfair ... unfortunate experiences; such a movement can generate the network power to improve healthcare ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... with offices that serve communities in and around the greater Phoenix metropolitan region, ... Homeless Youth Connection. , The mission of the Homeless Youth Connection is to ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 A Small Business Innovative ... Institutes of Health (NIH) to Phoenix ... The grant will seek to determine an ... which utilizes electromagnetic waves to treat Alzheimer,s Disease. The ... technology to possibly treat other neurologic disorders such as ...
(Date:12/8/2016)... 2016  Economic growth in the United States will ... management executives in their December 2016 Semiannual Economic Forecast. ... that began in mid-2009, as indicated in the monthly ... . The manufacturing sector is optimistic about growth in ... industries, and the non-manufacturing sector indicates that 14 of ...
(Date:12/8/2016)... 2016  Hanson Research, an innovative leader in ... diffusion testing instruments for the pharmaceutical industry, announced ... Inc. ("Teledyne"). The move is designed to deepen ... instruments, as well as expand resources for further ... and services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
Breaking Medicine Technology: